Changeflow GovPing Pharma & Drug Safety Class I Recall: UDENYCA by McKesson
Urgent Enforcement Added Final

Class I Recall: UDENYCA by McKesson

Favicon for changeflow.com drug-class-i
Filed January 16th, 2026
Detected March 27th, 2026
Email

Summary

The FDA has initiated a Class I recall for UDENYCA (pegfilgrastim-cbqv injection) distributed by McKesson due to temperature abuse. The recall affects 116 cartons from Lot 2199821 that were stored incorrectly, posing a potential health risk.

What changed

The Food and Drug Administration (FDA) has classified a recall of UDENYCA (pegfilgrastim-cbqv injection) initiated by McKesson as a Class I recall, indicating a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death. The recall, identified by recall number D-0353-2026, pertains to 116 cartons from Lot 2199821 due to improper storage conditions (temperature abuse), where the product was kept at controlled room temperature instead of the required refrigerated environment.

This action requires immediate attention from entities involved in the distribution and handling of this product. McKesson has initiated a voluntary recall, and affected parties must ensure that the specified serial numbers from Lot 2199821 are removed from circulation. While the recall is ongoing, the classification as Class I signifies the highest level of risk, necessitating prompt action to prevent patient exposure to potentially compromised medication. Compliance officers should verify their inventory and return procedures for this product and similar temperature-sensitive pharmaceuticals.

What to do next

  1. Verify inventory for affected UDENYCA product (Lot 2199821, specific serial numbers).
  2. Remove affected product from circulation and follow return procedures.
  3. Review and reinforce cold chain storage protocols for all temperature-sensitive pharmaceuticals.

Source document (simplified)

json
{
"meta": {
"disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
"terms": "https://open.fda.gov/terms/",
"license": "https://open.fda.gov/license/",
"last_updated": "2026-03-18",
"results": {
"skip": 0,
"limit": 1,
"total": 1
}
},
"results": [
{
"status": "Ongoing",
"city": "Irving",
"state": "TX",
"country": "United States",
"classification": "Class I",
"openfda": {
},
"product_type": "Drugs",
"event_id": "98366",
"recalling_firm": "McKesson",
"address_1": "6555 State Highway 161",
"address_2": "N/A",
"postal_code": "75039-2402",
"voluntary_mandated": "Voluntary: Firm initiated",
"initial_firm_notification": "E-Mail",
"distribution_pattern": "Nationwide in the USA",
"recall_number": "D-0353-2026",
"product_description": "UDENYCA, pegfilgrastim-cbqv injection, 6 mg/0.6mL Single Dose Prefilled Syringe, Rx only, Manufactured by Accord BioPharma, Inc., 8041 Arco Corporate Drive, Suite 200, Raleigh, NC 27617, NDC 69448-025-63",
"product_quantity": "116 cartons",
"reason_for_recall": "Temperature Abuse. 116 cartons with specific serial numbers of Lot 2199821, were stored incorrectly in a controlled room temperature environment instead of the required refrigerated environment.",
"recall_initiation_date": "20260116",
"center_classification_date": "20260226",
"report_date": "20260218",
"code_info": "Subset of Lot 2199821, Expires: 05/31/2027 Specific Serial Numbers being Recalled: 160R694TT06X; 1C74A686RPPG; 1W6A2M777N3V; 20825394KR8P; 242E2RK3EA92; 2DG49VH89EPG; 2WEA2ADK1P4H; 3KR2TVAG3VDH; 42M0V0G9PM84; 46E9XKDPTH1R; 4AM12WEAE48H; 4FGHR096DMNV; 4MWGWM991XNA; 4NEW8XD9DNM2; 4Y2PYDFN9YA1; 61EPX42R4K2A; 63FN9VW5CAV7; 69TG160DW2CV; 69XFP3TMTP7X; 6AWVDCNHTV61; 6CEFY72W5GPA; 6FHF1A59X0X4; 6GA64FNDVGXY; 6NW5FACPPWDW; 75V19CF2A0PA; 7HK7155YNAK3; 7R51VVA1WX9T; 7XCKXMH2EERC; 85D8MFVM66D4; 8F3Y5NFFHC64; 8RDWKPM53N5R; 8W1PVXC5NAFW; 9338DPED7P3R; 9A4CXFTGCPYN; 9FKN5NRDX99A; 9G79AR0RGAY4; 9K28G80GGYXN; 9NN7NXE40M13; A48PXEPE77YE; A8M168K58G64; AMR0RNWHTWMW; AR145NW8WTVX; AY19W6DEGRX4; C276HMDGRE49; CAY0ARAEGMCF; CKT370X2G4NP; D0DFAXCN6G5W; D54TXR8AD9Y8; DAK3XP1P3DMP; DH44AGKTX27F; E69E9K6C29VD; EK1D8P703RCH; EX947FYVW7Y6; F2K148YVNRDD; F4EVX8573F1V; FEXA7MENKWF1; FNDNMPAFH89D; G2W3WTMP5HK9; G5MN0F418FFY; G6XECANG6P01; G7FNVGWW3D72; GAHFFNX336GA; GKNTDP4AV6AA; GVPN5C4D23H6; GVPPYARK1FCD; GVXDAAA87GA1; GX7AP73W4HMH; HDTFT2W59K52; HDVG3W6VW59Y; HP703MKWGGM7; K8CGDV1301TP; KN6Y35T0A198; KVGC92YVC6XF; KYCP1Y7CK4R4; MEY2VW5MC0N9; MGH40F2679X3; N11XGETGDAVM; N9DGTY65NFGN; NH9VM1K2ECGP; NNCFT59RD1KF; NVFCXRWHX93N; P3XY0RNV0VPY; P609NH6W670V; P9Y7926YN82A; PA88CCXMWCMG; PKADTN18YR1X; PM0YHNNK6P4T; R11TYM5VE9CK; R45AXAEK4TTN; R6C3533P943P; RMW35MXX4R4K; RX75F9DA58W4; RXRCRP9272DG; RXTH041DMT5D; T2FW4C24F364; T442NHDFD7H8; TC3443DCR4F8; TK8TRR8NT92A; TT8K21TGYFWY; V255NE533X59; V6MYKEA7HN7P; V764DEYM4RYP; VCPTYV1EF0R1; VECGDTDV1Y3A; VEE09A07R9X5; VEER64AW2C51; VRN2TE3HPK5N; WF14WA03FNT2; WTP5TKRGNFGW; WWPMXV50FRM4; X1DKP0T2AE1W; X59C5AV3VDTG; XKG3T7811TD2; Y0CYY950EYK8; YCRW0EPK620Y; YNYA64T18DPW."
}
]
}

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
FDA
Filed
January 16th, 2026
Instrument
Enforcement
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
D-0353-2026

Who this affects

Applies to
Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Recalls Cold Chain Management
Threshold
Class I recall
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Compliance
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Product Safety Drug Recalls

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when drug-class-i publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.